A unique medium chain triglyceride-containing micronutrient complex: Effects on migraine symptoms compared to quality of lif

Abstract

Purpose: Migraine headaches and associated symptoms are prevalent medical issues. Medium-chain triglyceride (MCT)/nootropic-based compounds have demonstrated benefits in multiple domains. This study assessed the potential relief provided from a unique, high-concentration MCT/nootropic component blend on migraine frequency, duration, secondary symptoms, and quality of life (QOL) during a 60-day clinical investigation. Methods: Forty (n=40) chronic migraine sufferers [migraineurs] were prospectively randomized to participate in the double-blinded study. Both intervention (n=30) and control (n=10) participants were required to maintain lifestyle patterns for the trial duration. Migraine surveys used electronic response forms to allow subjects increased ease and safety during the COVID-19 pandemic. Results. The intervention subjects experienced reduction in migraine episodes by 53%, from 11.6 to 5.4 per month, after 60 days of supplement use. The average episode duration decreased from 260 minutes to 158 minutes, a 39% improvement. Time lost due to severe migraine effect was reduced from an average of more than five days per month to just over two per month, a decrease of 55%. A combined measure of secondary symptoms, which aggregate to illustrate migraine intensity, also decreased according to subject rating by an average of 37%. Self-assessed QOL scales improved by 43% in the intervention cohort. The control subjects showed no significant changes in any measures. Conclusion: Consumption of a unique, nootropic brain complex significantly improved migraine symptoms, including episode frequency, duration, severity, and lost days due to dysfunction. The formulation also beneficially impacted secondary effects and self-reported QOL.